RavenQuest BioMed Inc.

OTC: RVVQF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#871 of 1,402 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ —GM —SS 23

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), balance-sheet leverage · ↓ Piotroski F, market scale

Methodology →

Revenue TTM

$1.1M

Rev growth YoY (TTM)

-3.8%

Net income (FY)

-$23.7M

Employees

—

Market cap

$1.2k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$976.6k1.3M CAD2018

Net income-$23.7M-30.5M CAD2018

Operating income-$13.3M-17.2M CAD2018

Total assets$28.7M37.7M CAD2018

Liabilities$11.7M15.3M CAD2018

Equity$17.0M22.4M CAD2018

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

RavenQuest BioMed Inc. booked $976.6k in FY2018 revenue, growing 1032% year over year — faster than 96% of Healthcare companies we track, at a -2423.9% net margin.

Peers · Healthcare

Bionik Laboratories Corp.——FusionPharm, Inc.——Biomagnetics Diagnostics Corp.——PsyBio Therapeutics Corp——

Key facts

CEODavid Allen Cross

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: RVVQF

Employees—

IPO date2018-03-05

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.